Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-11-16

AUTHORS

Atsuko Chihara, Atsushi Tanaka, Takeshi Morimoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Shinichiro Ueda, Koichi Node

ABSTRACT

BackgroundAnagliptin, a dipeptidyl peptidase-4 inhibitor, is reported to reduce the level of low-density lipoprotein cholesterol (LDL-C). The underlying mechanism of this effect and effect on lipid metabolism however remains uncertain.Aim and methodsWe therefore evaluate the effects of anagliptin on lipid metabolism-related markers compared with those of sitagliptin. The study was a secondary analysis using data obtained from the Randomized Evaluation of Anagliptin versus Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial. This trial in patients with type 2 diabetes at a high risk of cardiovascular events and on statin therapy showed that anagliptin reduced LDL-C levels to a greater extent than sitagliptin. Cholesterol absorption (campesterol and sitosterol) and synthesis (lathosterol) markers were measured at baseline and 52 weeks in the study cohort (n = 353).ResultsThere was no significant difference in the changes of campesterol or sitosterol between the two treatment groups (p = 0.85 and 0.55, respectively). Lathosterol concentration was increased significantly at 52 weeks with sitagliptin treatment (baseline, 1.2 ± 0.7 μg/mL vs. 52 weeks, 1.4 ± 1.0 μg/mL, p = 0.02), whereas it did not change in the anagliptin group (baseline, 1.3 ± 0.8 μg/mL vs. 52 weeks, 1.3 ± 0.7 μg/mL, p = 0.99). The difference in absolute change between the two groups showed a borderline significance (p = 0.06).ConclusionThese findings suggest that anagliptin reduces LDL-C level by suppressing excess cholesterol synthesis, even in combination with statin therapy.Trial registration ClinicalTrials.gov number NCT02330406. https://clinicaltrials.gov/ct2/show/NCT02330406; registered January 5, 2015. More... »

PAGES

158

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12933-019-0965-3

DOI

http://dx.doi.org/10.1186/s12933-019-0965-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1122658455

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31733647


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholesterol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholesterol, LDL", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dipeptidyl-Peptidase IV Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dyslipidemias", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phytosterols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sitagliptin Phosphate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sitosterols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, 849-8501, Saga, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412339.e", 
          "name": [
            "Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, 849-8501, Saga, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chihara", 
        "givenName": "Atsuko", 
        "id": "sg:person.013676443224.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013676443224.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, 849-8501, Saga, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412339.e", 
          "name": [
            "Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, 849-8501, Saga, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tanaka", 
        "givenName": "Atsushi", 
        "id": "sg:person.012413241515.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012413241515.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan", 
          "id": "http://www.grid.ac/institutes/grid.272264.7", 
          "name": [
            "Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morimoto", 
        "givenName": "Takeshi", 
        "id": "sg:person.011273662612.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011273662612.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan", 
          "id": "http://www.grid.ac/institutes/grid.272264.7", 
          "name": [
            "Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sakuma", 
        "givenName": "Mio", 
        "id": "sg:person.01041233531.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01041233531.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Diabetes, Endocrinology and Metabolism, Fukushima Medical University, Fukushima, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411582.b", 
          "name": [
            "Department of Diabetes, Endocrinology and Metabolism, Fukushima Medical University, Fukushima, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shimabukuro", 
        "givenName": "Michio", 
        "id": "sg:person.01233731752.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01233731752.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology and Diabetes Mellitus, Fukuoka University, Fukuoka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411497.e", 
          "name": [
            "Department of Endocrinology and Diabetes Mellitus, Fukuoka University, Fukuoka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nomiyama", 
        "givenName": "Takashi", 
        "id": "sg:person.01255040512.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255040512.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, Tomishiro Central Hospital, Tomigusuku, Japan", 
          "id": "http://www.grid.ac/institutes/grid.460111.3", 
          "name": [
            "Department of Cardiology, Tomishiro Central Hospital, Tomigusuku, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arasaki", 
        "givenName": "Osamu", 
        "id": "sg:person.0611455170.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611455170.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.267625.2", 
          "name": [
            "Department of Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ueda", 
        "givenName": "Shinichiro", 
        "id": "sg:person.012353001702.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012353001702.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, 849-8501, Saga, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412339.e", 
          "name": [
            "Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, 849-8501, Saga, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Node", 
        "givenName": "Koichi", 
        "id": "sg:person.01100453460.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100453460.13"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12020-014-0376-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022989679", 
          "https://doi.org/10.1007/s12020-014-0376-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41598-019-44885-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1117069698", 
          "https://doi.org/10.1038/s41598-019-44885-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12933-017-0607-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092156137", 
          "https://doi.org/10.1186/s12933-017-0607-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10557-018-6776-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100981423", 
          "https://doi.org/10.1007/s10557-018-6776-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-011-0088-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005706723", 
          "https://doi.org/10.1007/s12325-011-0088-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-11-16", 
    "datePublishedReg": "2019-11-16", 
    "description": "BackgroundAnagliptin, a dipeptidyl peptidase-4 inhibitor, is reported to reduce the level of low-density lipoprotein cholesterol (LDL-C). The underlying mechanism of this effect and effect on lipid metabolism however remains uncertain.Aim and methodsWe therefore evaluate the effects of anagliptin on lipid metabolism-related markers compared with those of sitagliptin. The study was a secondary analysis using data obtained from the Randomized Evaluation of Anagliptin versus Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial. This trial in patients with type 2 diabetes at a high risk of cardiovascular events and on statin therapy showed that anagliptin reduced LDL-C levels to a greater extent than sitagliptin. Cholesterol absorption (campesterol and sitosterol) and synthesis (lathosterol) markers were measured at baseline and 52\u00a0weeks in the study cohort (n\u2009=\u2009353).ResultsThere was no significant difference in the changes of campesterol or sitosterol between the two treatment groups (p\u2009=\u20090.85 and 0.55, respectively). Lathosterol concentration was increased significantly at 52\u00a0weeks with sitagliptin treatment (baseline, 1.2\u2009\u00b1\u20090.7\u00a0\u03bcg/mL vs. 52\u00a0weeks, 1.4\u2009\u00b1\u20091.0\u00a0\u03bcg/mL, p\u2009=\u20090.02), whereas it did not change in the anagliptin group (baseline, 1.3\u2009\u00b1\u20090.8\u00a0\u03bcg/mL vs. 52\u00a0weeks, 1.3\u2009\u00b1\u20090.7\u00a0\u03bcg/mL, p\u2009=\u20090.99). The difference in absolute change between the two groups showed a borderline significance (p\u2009=\u20090.06).ConclusionThese findings suggest that anagliptin reduces LDL-C level by suppressing excess cholesterol synthesis, even in combination with statin therapy.Trial registration ClinicalTrials.gov number NCT02330406. https://clinicaltrials.gov/ct2/show/NCT02330406; registered January 5, 2015.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12933-019-0965-3", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1031021", 
        "issn": [
          "1475-2840"
        ], 
        "name": "Cardiovascular Diabetology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "keywords": [
      "low-density lipoprotein cholesterol", 
      "LDL-C levels", 
      "type 2 diabetes", 
      "statin therapy", 
      "lipoprotein cholesterol", 
      "secondary analysis", 
      "lipid metabolism", 
      "dipeptidyl peptidase-4 inhibitors", 
      "peptidase-4 inhibitors", 
      "effects of anagliptin", 
      "metabolism-related markers", 
      "anagliptin group", 
      "REASON trial", 
      "cardiovascular events", 
      "Diabetes (ACCORD) trial", 
      "sitagliptin treatment", 
      "study cohort", 
      "borderline significance", 
      "cholesterol absorption", 
      "high risk", 
      "treatment groups", 
      "lathosterol concentration", 
      "synthesis markers", 
      "ConclusionThese findings", 
      "anagliptin", 
      "Randomized Evaluation", 
      "sitagliptin", 
      "cholesterol synthesis", 
      "therapy", 
      "absolute change", 
      "trials", 
      "significant differences", 
      "underlying mechanism", 
      "patients", 
      "diabetes", 
      "cholesterol", 
      "weeks", 
      "markers", 
      "metabolism", 
      "group", 
      "ResultsThere", 
      "cohort", 
      "levels", 
      "MethodsWe", 
      "differences", 
      "baseline", 
      "greater extent", 
      "treatment", 
      "risk", 
      "inhibitors", 
      "effect", 
      "changes", 
      "findings", 
      "evaluation", 
      "significance", 
      "study", 
      "campesterol", 
      "sitosterol", 
      "events", 
      "analysis", 
      "concentration", 
      "mechanism", 
      "combination", 
      "extent", 
      "data", 
      "absorption", 
      "synthesis"
    ], 
    "name": "Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial", 
    "pagination": "158", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1122658455"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12933-019-0965-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31733647"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12933-019-0965-3", 
      "https://app.dimensions.ai/details/publication/pub.1122658455"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:05", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_824.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12933-019-0965-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12933-019-0965-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12933-019-0965-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12933-019-0965-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12933-019-0965-3'


 

This table displays all metadata directly associated to this object as RDF triples.

294 TRIPLES      21 PREDICATES      116 URIs      103 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12933-019-0965-3 schema:about N02d29e733f144acd8ba8b56c335d2658
2 N0617796a6fdf467db282448b12592090
3 N07a5ae660e4049c58c220ba56e848602
4 N0a3667fb3ba942f4aecd8af78ee1a55a
5 N13f772ebf5474f1abf23bd054e47db49
6 N177b547f72064ebbaa5494c21dc8abe3
7 N212bc9acd8de426690e58d89236509a8
8 N39d19011e7564194bc2df9df53dc00bc
9 N6514e62fdf3c42eab91abf49fc84a714
10 N70733034feb24fcd9315f59461e98360
11 N81c1bfd0a9d84740b08c3b2d0bb2c4b3
12 N835b3fcdca0c4cda86119a1956c4ab53
13 N8ab5264ccc1a42f7b085d451b6673cf2
14 N9bae21a6e128476c98ebb4c208a31b11
15 Nb2bdf23b659a4eefa67834120990a61c
16 Ncb193454a7864e07b421efdc5910d570
17 Ne1eb904a084b453988c3270f475c2e5b
18 Ne65cf8b4f3234c73be31e760b06bc6b9
19 Ned673ccc6be740438897f2088a78b84c
20 anzsrc-for:11
21 anzsrc-for:1103
22 schema:author Na79b4eec42f04097b61ffd37b8515d16
23 schema:citation sg:pub.10.1007/s10557-018-6776-z
24 sg:pub.10.1007/s12020-014-0376-x
25 sg:pub.10.1007/s12325-011-0088-z
26 sg:pub.10.1038/s41598-019-44885-x
27 sg:pub.10.1186/s12933-017-0607-6
28 schema:datePublished 2019-11-16
29 schema:datePublishedReg 2019-11-16
30 schema:description BackgroundAnagliptin, a dipeptidyl peptidase-4 inhibitor, is reported to reduce the level of low-density lipoprotein cholesterol (LDL-C). The underlying mechanism of this effect and effect on lipid metabolism however remains uncertain.Aim and methodsWe therefore evaluate the effects of anagliptin on lipid metabolism-related markers compared with those of sitagliptin. The study was a secondary analysis using data obtained from the Randomized Evaluation of Anagliptin versus Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial. This trial in patients with type 2 diabetes at a high risk of cardiovascular events and on statin therapy showed that anagliptin reduced LDL-C levels to a greater extent than sitagliptin. Cholesterol absorption (campesterol and sitosterol) and synthesis (lathosterol) markers were measured at baseline and 52 weeks in the study cohort (n = 353).ResultsThere was no significant difference in the changes of campesterol or sitosterol between the two treatment groups (p = 0.85 and 0.55, respectively). Lathosterol concentration was increased significantly at 52 weeks with sitagliptin treatment (baseline, 1.2 ± 0.7 μg/mL vs. 52 weeks, 1.4 ± 1.0 μg/mL, p = 0.02), whereas it did not change in the anagliptin group (baseline, 1.3 ± 0.8 μg/mL vs. 52 weeks, 1.3 ± 0.7 μg/mL, p = 0.99). The difference in absolute change between the two groups showed a borderline significance (p = 0.06).ConclusionThese findings suggest that anagliptin reduces LDL-C level by suppressing excess cholesterol synthesis, even in combination with statin therapy.Trial registration ClinicalTrials.gov number NCT02330406. https://clinicaltrials.gov/ct2/show/NCT02330406; registered January 5, 2015.
31 schema:genre article
32 schema:isAccessibleForFree true
33 schema:isPartOf N5edef21768ad419eb3e50849bbf0641e
34 Na39de2090f0a445b920ca08139d39399
35 sg:journal.1031021
36 schema:keywords ConclusionThese findings
37 Diabetes (ACCORD) trial
38 LDL-C levels
39 MethodsWe
40 REASON trial
41 Randomized Evaluation
42 ResultsThere
43 absolute change
44 absorption
45 anagliptin
46 anagliptin group
47 analysis
48 baseline
49 borderline significance
50 campesterol
51 cardiovascular events
52 changes
53 cholesterol
54 cholesterol absorption
55 cholesterol synthesis
56 cohort
57 combination
58 concentration
59 data
60 diabetes
61 differences
62 dipeptidyl peptidase-4 inhibitors
63 effect
64 effects of anagliptin
65 evaluation
66 events
67 extent
68 findings
69 greater extent
70 group
71 high risk
72 inhibitors
73 lathosterol concentration
74 levels
75 lipid metabolism
76 lipoprotein cholesterol
77 low-density lipoprotein cholesterol
78 markers
79 mechanism
80 metabolism
81 metabolism-related markers
82 patients
83 peptidase-4 inhibitors
84 risk
85 secondary analysis
86 significance
87 significant differences
88 sitagliptin
89 sitagliptin treatment
90 sitosterol
91 statin therapy
92 study
93 study cohort
94 synthesis
95 synthesis markers
96 therapy
97 treatment
98 treatment groups
99 trials
100 type 2 diabetes
101 underlying mechanism
102 weeks
103 schema:name Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial
104 schema:pagination 158
105 schema:productId N702f1c95cdb04565999f8042ea802f59
106 Nb9991a90e3794bfa87cab772bf4cc7d5
107 Nd4b1930d602046a28e442195bdc9d82b
108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122658455
109 https://doi.org/10.1186/s12933-019-0965-3
110 schema:sdDatePublished 2022-11-24T21:05
111 schema:sdLicense https://scigraph.springernature.com/explorer/license/
112 schema:sdPublisher N51bc74cd0f4546a088edb14d8baf3711
113 schema:url https://doi.org/10.1186/s12933-019-0965-3
114 sgo:license sg:explorer/license/
115 sgo:sdDataset articles
116 rdf:type schema:ScholarlyArticle
117 N009a5c111ddd4b489fc9d59f870d2c44 rdf:first sg:person.01255040512.80
118 rdf:rest Ne711fc18e0ca4dd682b3ad604d8412dd
119 N02d29e733f144acd8ba8b56c335d2658 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Cholesterol
121 rdf:type schema:DefinedTerm
122 N0617796a6fdf467db282448b12592090 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Biomarkers
124 rdf:type schema:DefinedTerm
125 N07a5ae660e4049c58c220ba56e848602 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Sitagliptin Phosphate
127 rdf:type schema:DefinedTerm
128 N0a1e238844834e329efb20709813ce66 rdf:first sg:person.012413241515.35
129 rdf:rest N1e77d727f8f74f1bb254efffe23b2f7f
130 N0a3667fb3ba942f4aecd8af78ee1a55a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Japan
132 rdf:type schema:DefinedTerm
133 N13f772ebf5474f1abf23bd054e47db49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Phytosterols
135 rdf:type schema:DefinedTerm
136 N177b547f72064ebbaa5494c21dc8abe3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Cholesterol, LDL
138 rdf:type schema:DefinedTerm
139 N1e77d727f8f74f1bb254efffe23b2f7f rdf:first sg:person.011273662612.03
140 rdf:rest N6adc834243a94903b93409210e5f53dc
141 N212bc9acd8de426690e58d89236509a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Sitosterols
143 rdf:type schema:DefinedTerm
144 N39d19011e7564194bc2df9df53dc00bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Diabetes Mellitus, Type 2
146 rdf:type schema:DefinedTerm
147 N3c3b1eef3e6f4c65b77007abf69f399f rdf:first sg:person.012353001702.96
148 rdf:rest Na353c910cbe64c679dc71db467098a7f
149 N51bc74cd0f4546a088edb14d8baf3711 schema:name Springer Nature - SN SciGraph project
150 rdf:type schema:Organization
151 N5edef21768ad419eb3e50849bbf0641e schema:issueNumber 1
152 rdf:type schema:PublicationIssue
153 N6514e62fdf3c42eab91abf49fc84a714 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Humans
155 rdf:type schema:DefinedTerm
156 N6adc834243a94903b93409210e5f53dc rdf:first sg:person.01041233531.06
157 rdf:rest Nbc731d49fcf94263ac0ac74e8e841311
158 N702f1c95cdb04565999f8042ea802f59 schema:name doi
159 schema:value 10.1186/s12933-019-0965-3
160 rdf:type schema:PropertyValue
161 N70733034feb24fcd9315f59461e98360 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Dyslipidemias
163 rdf:type schema:DefinedTerm
164 N81c1bfd0a9d84740b08c3b2d0bb2c4b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Pyrimidines
166 rdf:type schema:DefinedTerm
167 N835b3fcdca0c4cda86119a1956c4ab53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Hydroxymethylglutaryl-CoA Reductase Inhibitors
169 rdf:type schema:DefinedTerm
170 N8ab5264ccc1a42f7b085d451b6673cf2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Male
172 rdf:type schema:DefinedTerm
173 N9bae21a6e128476c98ebb4c208a31b11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Time Factors
175 rdf:type schema:DefinedTerm
176 Na353c910cbe64c679dc71db467098a7f rdf:first sg:person.01100453460.13
177 rdf:rest rdf:nil
178 Na39de2090f0a445b920ca08139d39399 schema:volumeNumber 18
179 rdf:type schema:PublicationVolume
180 Na79b4eec42f04097b61ffd37b8515d16 rdf:first sg:person.013676443224.16
181 rdf:rest N0a1e238844834e329efb20709813ce66
182 Nb2bdf23b659a4eefa67834120990a61c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Treatment Outcome
184 rdf:type schema:DefinedTerm
185 Nb9991a90e3794bfa87cab772bf4cc7d5 schema:name pubmed_id
186 schema:value 31733647
187 rdf:type schema:PropertyValue
188 Nbc731d49fcf94263ac0ac74e8e841311 rdf:first sg:person.01233731752.49
189 rdf:rest N009a5c111ddd4b489fc9d59f870d2c44
190 Ncb193454a7864e07b421efdc5910d570 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Dipeptidyl-Peptidase IV Inhibitors
192 rdf:type schema:DefinedTerm
193 Nd4b1930d602046a28e442195bdc9d82b schema:name dimensions_id
194 schema:value pub.1122658455
195 rdf:type schema:PropertyValue
196 Ne1eb904a084b453988c3270f475c2e5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Middle Aged
198 rdf:type schema:DefinedTerm
199 Ne65cf8b4f3234c73be31e760b06bc6b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Aged
201 rdf:type schema:DefinedTerm
202 Ne711fc18e0ca4dd682b3ad604d8412dd rdf:first sg:person.0611455170.93
203 rdf:rest N3c3b1eef3e6f4c65b77007abf69f399f
204 Ned673ccc6be740438897f2088a78b84c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Female
206 rdf:type schema:DefinedTerm
207 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
208 schema:name Medical and Health Sciences
209 rdf:type schema:DefinedTerm
210 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
211 schema:name Clinical Sciences
212 rdf:type schema:DefinedTerm
213 sg:journal.1031021 schema:issn 1475-2840
214 schema:name Cardiovascular Diabetology
215 schema:publisher Springer Nature
216 rdf:type schema:Periodical
217 sg:person.01041233531.06 schema:affiliation grid-institutes:grid.272264.7
218 schema:familyName Sakuma
219 schema:givenName Mio
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01041233531.06
221 rdf:type schema:Person
222 sg:person.01100453460.13 schema:affiliation grid-institutes:grid.412339.e
223 schema:familyName Node
224 schema:givenName Koichi
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100453460.13
226 rdf:type schema:Person
227 sg:person.011273662612.03 schema:affiliation grid-institutes:grid.272264.7
228 schema:familyName Morimoto
229 schema:givenName Takeshi
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011273662612.03
231 rdf:type schema:Person
232 sg:person.01233731752.49 schema:affiliation grid-institutes:grid.411582.b
233 schema:familyName Shimabukuro
234 schema:givenName Michio
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01233731752.49
236 rdf:type schema:Person
237 sg:person.012353001702.96 schema:affiliation grid-institutes:grid.267625.2
238 schema:familyName Ueda
239 schema:givenName Shinichiro
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012353001702.96
241 rdf:type schema:Person
242 sg:person.012413241515.35 schema:affiliation grid-institutes:grid.412339.e
243 schema:familyName Tanaka
244 schema:givenName Atsushi
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012413241515.35
246 rdf:type schema:Person
247 sg:person.01255040512.80 schema:affiliation grid-institutes:grid.411497.e
248 schema:familyName Nomiyama
249 schema:givenName Takashi
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255040512.80
251 rdf:type schema:Person
252 sg:person.013676443224.16 schema:affiliation grid-institutes:grid.412339.e
253 schema:familyName Chihara
254 schema:givenName Atsuko
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013676443224.16
256 rdf:type schema:Person
257 sg:person.0611455170.93 schema:affiliation grid-institutes:grid.460111.3
258 schema:familyName Arasaki
259 schema:givenName Osamu
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611455170.93
261 rdf:type schema:Person
262 sg:pub.10.1007/s10557-018-6776-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1100981423
263 https://doi.org/10.1007/s10557-018-6776-z
264 rdf:type schema:CreativeWork
265 sg:pub.10.1007/s12020-014-0376-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1022989679
266 https://doi.org/10.1007/s12020-014-0376-x
267 rdf:type schema:CreativeWork
268 sg:pub.10.1007/s12325-011-0088-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1005706723
269 https://doi.org/10.1007/s12325-011-0088-z
270 rdf:type schema:CreativeWork
271 sg:pub.10.1038/s41598-019-44885-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1117069698
272 https://doi.org/10.1038/s41598-019-44885-x
273 rdf:type schema:CreativeWork
274 sg:pub.10.1186/s12933-017-0607-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092156137
275 https://doi.org/10.1186/s12933-017-0607-6
276 rdf:type schema:CreativeWork
277 grid-institutes:grid.267625.2 schema:alternateName Department of Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan
278 schema:name Department of Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan
279 rdf:type schema:Organization
280 grid-institutes:grid.272264.7 schema:alternateName Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan
281 schema:name Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan
282 rdf:type schema:Organization
283 grid-institutes:grid.411497.e schema:alternateName Department of Endocrinology and Diabetes Mellitus, Fukuoka University, Fukuoka, Japan
284 schema:name Department of Endocrinology and Diabetes Mellitus, Fukuoka University, Fukuoka, Japan
285 rdf:type schema:Organization
286 grid-institutes:grid.411582.b schema:alternateName Department of Diabetes, Endocrinology and Metabolism, Fukushima Medical University, Fukushima, Japan
287 schema:name Department of Diabetes, Endocrinology and Metabolism, Fukushima Medical University, Fukushima, Japan
288 rdf:type schema:Organization
289 grid-institutes:grid.412339.e schema:alternateName Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, 849-8501, Saga, Japan
290 schema:name Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, 849-8501, Saga, Japan
291 rdf:type schema:Organization
292 grid-institutes:grid.460111.3 schema:alternateName Department of Cardiology, Tomishiro Central Hospital, Tomigusuku, Japan
293 schema:name Department of Cardiology, Tomishiro Central Hospital, Tomigusuku, Japan
294 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...